



Optieum Biotechnologies Inc.

Company Description

Optieum Biotechnologies Inc. is a pre-clinical stage biotechnology company committed to developing innovative scFv antibody-based therapies for the treatment of patients with cancers. Our proprietary platform technology, Eumbody System™, enables to develop and detect a scFv-based product candidates that specifically bind to, and modulate to optimize the immune-cell function for oncology targets.

We are committed to help patients with severe diseases by bringing life-changing therapies to the patients in need.

Eumbody System™

Optieum Biotechnologies's Eumbody System™ is a proprietary platform technology for the development of next-generation scFv antibody.

Our technology enables to generate the new scFv expressing CAR-T cells with greater proliferation capacity and longevity, enabling superior reactivity against advanced tumors and minimized adverse effects.

We are open for a partnership to jointly develop a next generation immuno-oncology products.

Company Details

Head Office

Japan

Main Business

バイオ医薬品

President

西岡 駿

Established

2020 年 6 月 30 日

URL

<https://optieumbio.com/#main>

Offices

Main Office

454 Shitsukawa, Toon-shi
Ehime, Japan, 7910204